1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4 - Implications for susceptibility to Parkinson's disease

Journal of Pharmacology and Experimental Therapeutics

Volumn 277, Issue 2, 1996, Pages 685-690

  Coleman, T ^a   Ellis, S W ^a   Martin, I J ^b   Lennard, M S ^a   Tucker, G T ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b Upjohn Laboratories Europe   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 ISOENZYME; KETOCONAZOLE; N DEMETHYLASE; QUINIDINE;

ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DISEASE PREDISPOSITION; DRUG DETOXIFICATION; DRUG OXIDATION; HUMAN; HUMAN CELL; LIVER MICROSOME METABOLISM; NEUROTOXICITY; PARKINSON DISEASE; PRIORITY JOURNAL; TOXICOKINETICS;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DEALKYLATION; HUMANS; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; MPTP POISONING; OXIDOREDUCTASES; PARKINSON DISEASE;

EID: 0030436624     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. ARMSTRONG, M., DALY, A. K., CHOLERTON, S., BATEMAN, D. N. AND IDLE, J. C.: Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 339: 1017-1018, 1992.
2. BALDWIN, S. J., BLOOMER, J. C., SMITH, G. J., AYRTON, A. D., CLARKE, S. E. AND CHENERY, R. J.: Ketoconazole and sulphaphenazole as the respective inhibitors of P4503A and 2C9. Xenobiotica 25: 261-270, 1995.
3. BARBEAU, A., CLOUTIER, T., PLASSE, L., ROY, M., PARIS, S. AND POIRIER, J.: Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine. Lancet 2: 1213-1215, 1985.
4. CASHMAN, J., R. AND ZIEGLER, D. M.: Contribution of N-oxygenation to the metabolism of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) by various liver preparations. Mol. Pharmacol. 29: 163-167, 1986.
5. CHIBA, K., KUBOTA, E., MIYAKAWA, T., KATO, Y. AND ISHIZAKI, T.: Characterization of hepatic microsomal metabolism as an in vivo detoxification pathway of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. J. Pharmacol. Exp. Ther. 246: 1108-1115, 1988.
6. CHIBA, K., HORII, H., KUBOTA, E., ISHIZAKI, T. AND KATO, Y.,: Effects of N-methylmercaptoimidazole on the disposition of MPTP and its metabolites in mice. Eur. J. Pharmacol. 180: 59-67, 1990.
7. CHIBA, K., TREVOR, A. AND CASTAGNOLI, JR., N.: Metabolism of the neurotoxic tertiary amine, MPTP, by brain monooxidase. Biochem. Biophys. Res. Commun. 120: 574-578, 1984.
8. CHING M. S., LENNARD M. S., TUCKER G. T., WOODS, H. F., KELLY, D. E. AND KELLY, S. L: The expression of human cytochrome P4501A1 in the yeast Saccromyces cerevisiae. Biochem. Pharmacol. 42: 753-758, 1991.
9. CLARKE, S. E., AYRTON, A. D. AND CHENERY, R. J.: Characterization of the inhibition of P4501A2 by furafylline. Xenobiotica 24: 517-526, 1994.
10. COLLINS, M. A. AND NEAFSEY, E. J.: Beta-carboline analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): Endogenous factors underlying parkinsonism? Neurosci Lett. 55: 179-184, 1985.
11. COUTTS, R. T., SU, P. AND BAKER, G. B.: Involvement of CYP2D6, CYP3A4 and other cytochrome P-450 isozymes in N-dealkylation reactions. J. Pharmacol. Toxicol. Metab. 31: 177-186, 1994.
12. DAS, N. P., SHAHI, G. S AND MOOCHHALA, S. M.: Effect of MPTP and its toxic metabolites on the physicochemical property of the liposomal membrane in relation to their cytochrome P-450 inhibition. Chem. Phys. Lipids 62: 303-310, 1992.
13. DI MONTE, D., SHINKA, T., SANDY, M. S., CASTAGNOLI JR, N. AND SMYTH, M. T.: Quantitative analysis of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine metabolism in isolated rat hepatocytes. Drug Metab. Dispos. 16: 2150-2155, 1988.
14. ELLIS, S. W., CHING, M. S., WATSON, P. F., HENDERSON, C. J., SIMULA, A. P., LENNARD, M. S., TUCKER, G. T. AND WOODS, H. F.: Catalytic activities of human debrisoquine 4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeast. Biochem. Pharmacol. 44: 617-620, 1992.
15. FONNE-PFISTER, R., BARGETZI, M. J. AND MEYER, U. A.. MPTP, the neurotoxin inducing Parkinson's Disease, is a potent inhibitor of human and rat cytochrome P450 isozymes (P450buf1, P450dbl) catalyzing debrisoquine-4-hydroxylation. Biochem. Biophys. Res. Commun. 148: 1144-1150, 1987.
16. GODWIN-AUSTEN, R B., LEE, P. N., MARMOT, M. G. AND STERN, G. M.: Smoking and Parkinson's disease. J. Neurol. Neurosurg. Psych. 45: 577-581, 1982.
17. GUDJONSSON, O., SANZ, E., ALVAN, G., AQUILONIUS, S. M. AND REVIRIEGO, J.: Poor hydroxylator phenotypes of debrisoquine and S-mephenytoin are not overrepresented in a group of patients with Parkinson's disease. Br. J. Clin. Pharmacol. 30: 301-302, 1990.
18. GUENGERICH, F. P.: Cytochromes P450 of human liver. Classification and activity profiles of the major enzymes. In Advances in Drug Metabolism in Man, ed. by G. M. Pacifici and G. N. Fracchia, pp. 180-231, Office for Official Publications of the European Communities, Luxembourg, 1995.
19. HEIKKILA, R. E., MANZINO, L., CABBAT, F. S. AND DUVOISIN, R. C.: Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and several of its analogues on the dopaminergic nigrostriatal pathway in mice. Neurosci. Lett. 58: 133-137, 1985.
20. JIMÉNEZ-JIMÉNEZ, F. J., TABERNERO, C., MENA, M. A., GARCÍA DE YÉBENES, M. J., CASAREJOS, M. J., PARDO, B., GARCÍA-AGUNDEZ, J. A., BENÍTEZ, J., MARTÍNEZ, A. AND GARCÍA-ASENJO J. A. L.: Acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in a model of rat designated as a poor metaboliser of debrisoquine. J. Neurochem. 57: 81-87, 1991.
21. KALLIO, J., MARTILLA, R. J., RINNE, U. K., SONNINEN, V. AND SYVALAHTI, E.: Debrisoquine oxidation in Parkinson's disease. Acta Neurol. Scand. 83: 194-197, 1991
22. KOYMANS, L., VERMEULEN, N. P. E., VAN ACKER, S. A. B. E., TE KOPPELE, J. M., HEYKANTS, J. J. P., LAVRIJSEN, K., MEULDERMANS, W. AND DEN KIEDER, G. M. D.: A predictive model for substrates of cytochrome P450-debrisoquine (2D6). Chem. Res. Toxicol. 5: 211-219, 1992.
23. LANGSTON, J. W., IRWIN, I., LANGSTON, E. AND FORNO, L. S.: Identification of a metabolite of MPTP a toxin selective to the substantia nigra. Neurosci. Lett. 48: 87-92 1984.
24. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L.: Protein measurement with the folin phenol reagent. J. Biol. Chem. 193: 265-275, 1951.
25. METZLER C. M. NONLIN.: Technical report No. 7292/69/7291/005. Kalamazoo, MI: The Upjohn Co. 111, 1974.
26. +) and the structurally related compounds in vitro and in vivo. Eur. J. Neurol. 26: (Suppl 1), 11-15, 1987.
27. OTTOBONI, S., CARLSEN, T. J., TRAGER, W. F., CASTAGNOLI, K. AND CASTAGNOLI, N.: Studies on the cytochrome P-450 catalyzed ring alpha-carbon oxidation of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Chem. Res. Toxicol. 3: 423-427, 1990.
28. OTTON S. V., CREWE H. K., LENNARD M. S., TUCKER, G. T. AND WOODS, H. F.: Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P-450 in metoprolol oxidation by human liver microsomes. J. Pharmacol. Exp. Ther. 247: 242-247, 1988.
29. PERRY, T. L., JONES, K., HANSEN, S. AND WALL, R. A.: 4-phenylpyridine and three other analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahyoropyridine lack dopaminergic nigrostriatal neurotoxicity in mice and marmosets. Neurosci Lett. 75: 65-70, 1987.
30. RAVINDRANATH, V. AND BOYD, M. R.: Xenobiotic metabolism in brain. Drug Metab. Rev. 27: 419-448, 1995.
31. SESARDIC D., EDWARDS R. J., DAVIES D. S., THOMAS P. E., LEVIN W. AND BOOBIS A. R.: High affinity phenacetin O-deethylase is catalysed specifically by cytochrome P450d (P4501A2) in the liver of rat. Biochem. Pharmacol. 39: 489-498, 1990.
32. SMITH, C. A. D., GOUGH, A. C., LEIGH, P. N., SUMMERS, B. A., HARDING, A. E , MARANGANORE, D. M., STURMAN, S. G., SCHAPIRA, A. H. V., WILLIAMS, A. C., SPURR, N. K. AND WOLFF, C. R.: Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinsons disease. Lancet 1: 1375-1377, 1992.
33. STEIGER, M. J., LLEDO, P., QUINN, N. P., TURNER, P. AND JENNER, P. G.: Debrisoquine hydroxylation in Parkinson's disease. Acta Neurol. Scand. 86: 159-164, 1992.
34. SUSUKI, T., FUJITA, S., NARIMATSU, S., MASUBUCHI, Y., TACHIBANA, M., OHTA, S. AND HIROBE, M.: Cytochrome P450 isozymes catalysing the 4-hydroxylation of parkinsonian-related compound 1,2,3,4-tetrahydroisoquinoline in rat liver microsomes. FASEB J. 6: 771-776, 1992.
35. WAXMAN, D. J., ATTISANO, C., GUENGERICH, J. R. AND LAPENSON, D. P.: Human liver microsomal steroid metabolism: Identification of the major microsomal steroid hormone 6β-hydroxylase cytochrome P450 enzyme. Arch. Biochem. Biophys. 263: 424-436, 1988.
36. WEISSMAN, J., TREVOR, A., CHIBA, K., PETERSON, L. A., CALDERA, P. AND CASTAGNOLI, JR , N.: Metabolism of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by liver homogenate fractions. J. Med. Chem. 28: 997-1001, 1985.
37. WILLIAMS, M. L., LENNARD, M. S., MARTIN, I J. AND TUCKER, G. T.: Intel-individual variation in the isomerization of 4-hydroxytamoxifen by human liver microsomes: involvement of cytochrome P450. Carcinogenesis, 15: 2733-2738, 1994.